Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC008-1A in Advanced Solid Tumors (Esophageal and NSCLC)
NCT06773507Phase 1Recruiting
- Sponsor
- Sichuan Luzhou Buchang Biopharmaceutical
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BC008-1A in Esophageal Squamous Cell Carcinoma (ESCC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sichuan Luzhou Buchang Biopharmaceutical. Primary endpoint: Objective Response Rate up to 2 years. Started May 2025; status: recruiting.
02
Drugs
BC008-1A
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06773507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06773507.